Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus

European Journal of Clinical Pharmacology

Volumn 68, Issue 6, 2012, Pages 961-968

  Bardin, Christophe ^a   Nobecourt, Estelle ^a   Larger, Etienne ^a   Chast, François ^a   Treluyer, Jean Marc ^b,c   Urien, Saik ^b,c  

^a HÔTEL DIEU   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Diabetology; Metformin; Obese patient; Population pharmacokinetics; Size descriptors

Indexed keywords

CREATININE; METFORMIN; METFORMIN EMBONATE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY WEIGHT; CREATININE BLOOD LEVEL; DATA ANALYSIS SOFTWARE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NONLINEAR DYNAMICS; OBESITY;

EID: 84864287169     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1207-0     Document Type: Article

References (28)

1. Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32:193-203
2. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in human. Clin Pharmacokinet 49:71-87
3. Cheymol G (2000) Effects of obesity on pharmacokinetics. Clin Pharmacokinet 39:215-231
4. Sparreboom A, Wolff AC, Mathijssen RHJ et al (2010) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707-4713 (Pubitemid 350086471)
5. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL (1997) Efficacy of metformin in type II diabetes: results of a double-blind, placebo controlled, dose response trial. Am J Med 103:491-497 (Pubitemid 28018651)
6. Graham GG, Punt J, Arora M et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81-98
7. Devine D (1974) Case study number 25 gentamicin therapy. Drug Intell Clin Pharm 8:650-655
8. Janmahasatian S, Dufull SB, Ash S et al (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051-1065 (Pubitemid 41356391)
9. Amini H, Ahmadiani A, Gazerani P (2005) Determination of metformin in human plasma by high-performance liquid chromatography. J Chrom B 824:319-322 (Pubitemid 41215613)
10. Kuhn E, Lavielle M (2005) Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 49:1020-1030
11. R Development Core Team (2009) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
12. McLeay S, Morrish G, Kirkpatrick C et al (2009) Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res 26:1626-1634
13. Mould D, Holford N, Schellens J et al (2002) Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71:334-348 (Pubitemid 34518144)
14. Sirtori CR, Franceschini G, Galli-Kienle M et al (1978) Disposition of metformin (N, N-dimethylbiguanide) in man. Clin Pharmacol Ther 24:683-693
15. Pentikaïnen PJ, Neuvonen PJ, Pentillä A (1979) Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 16:195-202 (Pubitemid 10227380)
16. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235-246 (Pubitemid 11034446)
17. Scheen AJ (1996) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30:359-371 (Pubitemid 26177181)
18. Hong Y, Rohatagi S, Habtemariam B, Walker J, Schwartz SL, Mager DE (2008) Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol 48:696-707 (Pubitemid 351713153)
19. Schäfer G (1983) Biguanides: a review of history, pharmacodynamics and therapy. Diab Metab 9:148-163 (Pubitemid 14107974)
20. Han PY, Duffull SB, Kirkpatrick CM, Green B (2007) Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 82:505-508 (Pubitemid 47622534)
21. Erstadt BL (2004) Dosing of medications in morbidly obese patients in intensive care unit setting. Intensive Care Med 30:18-32
22. Traynor AM, Nafziger AN, Bertino JS (1995) Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39:545-548
23. Green B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119-133 (Pubitemid 39043992)
24. Sambol NC, Chiang J, Lin ETet al (1995) Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 35:1094-1102
25. Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J (1990) Type 2 diabetes in the elderly: an assessment of metformin. Int J Clin Pharmacol Ther Toxico 28:329-332 (Pubitemid 20293300)
26. Karim A, Slater M, Bradford D et al (2007) Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systematic exposures of each drug. J Clin Pharmacol 47:37-47 (Pubitemid 44973996)
27. Sambol NC, Brookes LG, Chiang J et al (1996) Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 42:510-512 (Pubitemid 26340155)
28. Tzvetkov MV, Vormfelde SV, Balen B et al (2009) The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2 and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 86:299-306